WallStSmart

CareTrust REIT Inc. (CTRE)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 545% more annual revenue ($3.07B vs $476.39M). CTRE leads profitability with a 67.3% profit margin vs 16.1%. CTRE appears more attractively valued with a PEG of 1.26. CTRE earns a higher WallStSmart Score of 76/100 (B+).

CTRE

Strong Buy

76

out of 100

Grade: B+

Growth: 10.0Profit: 8.0Value: 10.0Quality: 7.0
Piotroski: 3/9Altman Z: 2.46

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CTREUndervalued (+41.5%)

Margin of Safety

+41.5%

Fair Value

$67.39

Current Price

$37.14

$30.25 discount

UndervaluedFair: $67.39Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$245.27

$176.28 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTRE6 strengths · Avg: 9.5/10
Profit MarginProfitability
67.3%10/10

Keeps 67 of every $100 in revenue as profit

Operating MarginProfitability
67.1%10/10

Strong operational efficiency at 67.1%

Revenue GrowthGrowth
55.1%10/10

Revenue surging 55.1% year-over-year

EPS GrowthGrowth
77.1%10/10

Earnings expanding 77.1% YoY

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

CTRE2 concerns · Avg: 3.5/10
P/E RatioValuation
25.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CTRE

The strongest argument for CTRE centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 67.3% and operating margin at 67.1%. Revenue growth of 55.1% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : CTRE

The primary concerns for CTRE are P/E Ratio, Piotroski F-Score.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

CTRE profiles as a growth stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

CTRE is growing revenue faster at 55.1% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

CTRE scores higher overall (76/100 vs 55/100), backed by strong 67.3% margins and 55.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CareTrust REIT Inc.

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

CareTrust REIT, Inc. is a publicly traded, self-managed real estate investment trust engaged in the ownership, acquisition, development, and leasing of skilled nursing, senior housing, and other healthcare-related properties.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?